Tandem Diabetes Care Inc. (NASDAQ:TNDM) traded down 13.9% during mid-day trading on Friday . The stock traded as low as $6.62 and last traded at $6.70, with a volume of 437,868 shares traded. The stock had previously closed at $7.78.

Several equities research analysts have issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Friday. Robert W. Baird reiterated a “buy” rating on shares of Tandem Diabetes Care in a research note on Monday, May 2nd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Wednesday, May 4th. Sterne Agee CRT reiterated a “neutral” rating on shares of Tandem Diabetes Care in a research note on Monday, May 16th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $12.00 price objective on shares of Tandem Diabetes Care in a research note on Thursday, April 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. Tandem Diabetes Care currently has a consensus rating of “Buy” and a consensus target price of $14.21.

The stock’s market capitalization is $201.23 million. The firm’s 50-day moving average is $7.55 and its 200 day moving average is $8.22.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.05. During the same quarter in the prior year, the business posted ($0.65) EPS. The company earned $23 million during the quarter, compared to analysts’ expectations of $23.08 million. The company’s revenue was up 46.5% on a year-over-year basis. Analysts anticipate that Tandem Diabetes Care Inc. will post ($2.16) EPS for the current fiscal year.

A hedge fund recently raised its stake in Tandem Diabetes Care stock. Westfield Capital Management Co. LP increased its stake in Tandem Diabetes Care Inc. (NASDAQ:TNDM) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,125,281 shares of the medical device company’s stock after buying an additional 35,680 shares during the period. Westfield Capital Management Co. LP owned 3.74% of Tandem Diabetes Care worth $13,290,000 at the end of the most recent reporting period.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.